Evidence map›Paper›PMID 30521819›Full record

Observational studyToxicology and applied pharmacology2019

Metabolome-wide association study of anti-epileptic drug treatment during pregnancy.

Douglas I Walker, Kayla Perry-Walker, Richard H Finnell, Kurt D Pennell, Vilinh Tran, Ryan C May, Thomas F McElrath, Kimford J Meador, Page B Pennell, Dean P Jones

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Toxicology and applied pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Lipid nanoparticle GM-CSF replacement for autoimmune pulmonary alveolar proteinosis.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Sphinganine is associated with 24-h MAP in the non-sleepy with OSA.Metabolomics : Official journal of the Metabolomic Society · 2022
    Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Douglas I WalkerClinical Biomarkers Laboratory, Division of Pulmonary, Allergy, and Critical Care Medicine, Emory University School of Medicine, Atlanta, GA, United States; Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
Kayla Perry-WalkerDepartment of Obstetrics-Gynecology, Pennsylvania Hospital, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States.
Richard H FinnellDepartments of Molecular and Cellular Biology and Medicine, Baylor College of Medicine, Houston, TX, United States.
Kurt D PennellSchool of Engineering, Brown University, Providence, RI, United States.
Vilinh TranDepartment of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
Ryan C MayThe Emmes Corporation, Rockville, MD, United States.
Thomas F McElrathDivision of Maternal-Fetal Medicine, Department of Obstetrics-Gynecology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, United States.
Kimford J MeadorDepartment of Neurology, Stanford University, Stanford, CA, United States.
Page B PennellDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Dean P JonesClinical Biomarkers Laboratory, Division of Pulmonary, Allergy, and Critical Care Medicine, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: dpjones@emory.edu.

Funding

Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)U01NS038455 · NINDS · STANFORD UNIVERSITY · PI MATTHEWS, ABIGAIL GOREN, MEADOR, KIMFORD J · 2012 to 2022
$27.7M
Pilot Project ProgramP30ES019776 · NIEHS · EMORY UNIVERSITY · PI William Michael Caudle · 2013 to 2026
$22.6M
NEURODEVELOPMENT EFFECTS OF ANTIEPILEPTIC DRUGSR01NS038455 · NINDS · UNIVERSITY OF FLORIDA · PI MEADOR, KIMFORD J · 2000 to 2009
$12.0M
Graduate and Postdoctoral Training in ToxicologyT32ES012870 · NIEHS · EMORY UNIVERSITY · PI Carmen Joseph Marsit · 2004 to 2026
$9.1M
National Exposure Assessment Laboratory at EmoryU2CES026560 · NIEHS · EMORY UNIVERSITY · PI JONES, DEAN PAUL · 2015 to 2015
$8.3M
MONEAD Data and Statistical CenterU01NS050659 · NINDS · THE EMMES COMPANY, LLC · PI MAY, RYAN · 2012 to 2016
$3.5M
Neurodevelopment Effects of Antiepileptic DrugsR01NS050659 · NINDS · THE EMMES COMPANY, LLC · PI BROWNING, NANCY · 2004 to 2008
$2.5M
An environment-wide association study in autism spectrum disorders using novel bioinformatics methods and metabolomics via mass spectrometryR01MH107205 · NIMH · BOSTON CHILDREN'S HOSPITAL · PI KONG, SEK WON · 2015 to 2019
$2.1M
Orbitrap Elite/H-ESI BundleS10OD018006 · OD · EMORY UNIVERSITY · PI JONES, DEAN PAUL · 2014 to 2014
$600k
NIEHS NIH HHS P30 ES019776NIEHS NIH HHS T32 ES012870NIEHS NIH HHS U2C ES026560NIH HHS S10 OD018006NIMH NIH HHS R01 MH107205NINDS NIH HHS R01 NS038455NINDS NIH HHS R01 NS050659NINDS NIH HHS U01 NS038455NINDS NIH HHS U01 NS050659
6 · The paper itself

Abstract

Pregnant women with epilepsy (PWWE) require continuous anti-epileptic drug (AED) treatment to avoid risk to themselves and fetal risks secondary to maternal seizures, resulting in prolonged AED exposure to the developing embryo and fetus. The objectives of this study were to determine whether high-resolution metabolomics is able to link the metabolite profile of PWWE receiving lamotrigine or levetiracetam for seizure control to associated pharmacodynamic (PD) biological responses. Untargeted metabolomic analysis of plasma obtained from 82 PWWE was completed using high-resolution mass spectrometry. Biological alterations due to lamotrigine or levetiracetam monotherapy were determined by a metabolome-wide association study that compared patients taking either drug to those who did not require AED treatment. Metabolic changes associated with AED use were then evaluated by testing for drug-dose associated metabolic variations and pathway enrichment. AED therapy resulted in drug-associated metabolic profiles recognizable within maternal plasma. Both the parent compounds and major metabolites were detected, and each AED was correlated with other metabolic features and pathways. Changes in metabolites and metabolic pathways important to maternal health and linked to fetal neurodevelopment were detected for both drugs, including changes in one‑carbon metabolism, neurotransmitter biosynthesis and steroid metabolism. In addition, decreased levels of 5-methyltetrahydrofolate and tetrahydrofolate were detected in women taking lamotrigine, which is consistent with recent findings showing increased risk of autism spectrum disorder traits in PWWE using AED. These results represent a first step in development of pharmacometabolomic framework with potential to detect adverse AED-related metabolic changes during pregnancy.

Indexed as

AdultAnticonvulsantsCarbonEpilepsyFemaleFetusFolic AcidHumansLamotrigineLevetiracetamMetabolic Networks and PathwaysMetabolomeMetabolomicsNeurotransmitter AgentsPregnancyPregnancy ComplicationsAnticonvulsantsCarbonFolic AcidLamotrigineLevetiracetamNeurotransmitter AgentsSteroidsEpilepsyFolateHigh-resolution mass spectrometryLamotrigineLevetiracetamPharmacometabolomics

Identifiers

PMID30521819
PMCPMC7172934

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.